Scarica l'app Stockscreener
103.16
0.95%
-1.30
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché AXSM Giù?
Forum
Previsione
Precedente Chiudi:
$104.46
Aprire:
$103.55
Volume 24 ore:
495.17K
Relative Volume:
0.56
Capitalizzazione di mercato:
$5.05B
Reddito:
$338.46M
Utile/perdita netta:
$-310.96M
Rapporto P/E:
-15.80
EPS:
-6.53
Flusso di cassa netto:
$-132.82M
1 W Prestazione:
-0.06%
1M Prestazione:
-18.40%
6M Prestazione:
+13.08%
1 anno Prestazione:
+52.38%
Intervallo 1D:
$101.58
$104.17
Intervallo di 1 settimana:
$101.32
$105.66
Portata 52W:
$64.11
$139.13
Axsome Therapeutics Inc Stock (AXSM) Company Profile
Nome
Axsome Therapeutics Inc
Settore
Industria
Telefono
(212) 332-3241
Indirizzo
ONE WORLD TRADE CENTER, 22ND FLOOR, NEW YORK
Confronta AXSM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AXSM
Axsome Therapeutics Inc
|
103.30 | 5.05B | 338.46M | -310.96M | -132.82M | -6.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.90 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.43 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
598.50 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.19 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.99 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-07 | Iniziato | Jefferies | Buy |
| 2025-02-11 | Iniziato | Deutsche Bank | Buy |
| 2024-12-31 | Reiterato | Mizuho | Outperform |
| 2024-09-03 | Iniziato | Wells Fargo | Overweight |
| 2024-08-06 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-07-22 | Iniziato | Needham | Buy |
| 2024-04-29 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-03-19 | Iniziato | Robert W. Baird | Outperform |
| 2024-02-06 | Iniziato | UBS | Buy |
| 2024-01-25 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-12-13 | Iniziato | Citigroup | Buy |
| 2023-08-08 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2023-01-05 | Iniziato | Piper Sandler | Neutral |
| 2022-11-01 | Iniziato | Loop Capital | Buy |
| 2022-09-07 | Ripresa | Mizuho | Buy |
| 2021-08-10 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-06-10 | Iniziato | Berenberg | Buy |
| 2021-01-08 | Iniziato | Jefferies | Buy |
| 2020-12-16 | Iniziato | Mizuho | Buy |
| 2020-09-29 | Iniziato | BofA Securities | Underperform |
| 2020-09-10 | Iniziato | Morgan Stanley | Overweight |
| 2020-04-28 | Reiterato | H.C. Wainwright | Buy |
| 2020-04-14 | Iniziato | Cowen | Outperform |
| 2019-12-30 | Reiterato | H.C. Wainwright | Buy |
| 2019-12-17 | Reiterato | H.C. Wainwright | Buy |
| 2019-12-16 | Reiterato | Guggenheim | Buy |
| 2019-10-16 | Iniziato | Guggenheim | Buy |
| 2019-09-18 | Iniziato | William Blair | Outperform |
| 2019-05-28 | Iniziato | SunTrust | Buy |
| 2019-05-23 | Reiterato | H.C. Wainwright | Buy |
| 2019-04-08 | Iniziato | SVB Leerink | Outperform |
| 2019-03-15 | Reiterato | H.C. Wainwright | Buy |
| 2016-10-03 | Ripresa | Brean Capital | Buy |
| 2015-12-15 | Iniziato | Cantor Fitzgerald | Buy |
| 2015-12-14 | Iniziato | Ladenburg Thalmann | Buy |
Mostra tutto
Axsome Therapeutics Inc Borsa (AXSM) Ultime notizie
Russell Investments Group Ltd. Boosts Stock Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Leerink Partnrs Brokers Increase Earnings Estimates for AXSM - MarketBeat
Leerink Partnrs Has Pessimistic Outlook of AXSM Q1 Earnings - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Stock Holdings Lowered by Affinity Asset Advisors LLC - MarketBeat
Axsome slips as late-stage trial for depression therapy fails - MSN
1492 Capital Management LLC Purchases New Stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Kennedy Capital Management LLC Raises Stock Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
91,649 Shares in Axsome Therapeutics, Inc. (NASDAQ:AXSM) Purchased by Granite Investment Partners LLC - MarketBeat
Invesco Ltd. Increases Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
LPL Financial LLC Raises Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Stock Position Reduced by Alliancebernstein L.P. - MarketBeat
XTX Topco Ltd Makes New Investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Geode Capital Management LLC Raises Stock Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Trexquant Investment LP Acquires New Stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
This Little-Known Stock Could Be One of the Best Recession-Proof Investments Now - The Globe and Mail
Is Axsome Therapeutics (NASDAQ:AXSM) A Risky Investment? - simplywall.st
Kuehn Law Encourages Investors of Axsome Therapeutics, Inc. to Contact Law Firm - Kilgore News Herald
SECURITIES FRAUD CLASS ACTIONS HAVE SURVIVED MOTIONS TO - GlobeNewswire
SECURITIES FRAUD CLASS ACTIONS HAVE SURVIVED MOTIONS TO DISMISS: Long-Term Shareholders of Axsome Therapeutics, Inc. (NASDAQ: AXSM); Driven Bands Holdings, Inc. (NASDAQ: DRVN); Mercury Systems, Inc. (NASDAQ: MRCY); and Virtu Financial Inc. (NASDAQ: VIRT) Should Contact Grabar Law Office Today - GlobeNewswire Inc.
Zacks Research Analysts Decrease Earnings Estimates for AXSM - MarketBeat
What is Zacks Research's Forecast for AXSM FY2025 Earnings? - MarketBeat
American Century Companies Inc. Invests $570,000 in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics (NASDAQ:AXSM) Shares Down 6.9%What's Next? - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Bought by Franklin Resources Inc. - MarketBeat
Axsome Therapeutics (NASDAQ:AXSM) Now Covered by Analysts at Jefferies Financial Group - MarketBeat
ADAR1 Capital Management LLC Acquires 19,061 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Attention Long-Term Shareholders of Axsome Therapeutics, Inc. (NASDAQ: AXSM); Driven Bands - Bluefield Daily Telegraph
Attention Long-Term Shareholders of Axsome Therapeutics, - GlobeNewswire
Schroder Investment Management Group Sells 34,158 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome (AXSM) Moves 4.2% Higher: Will This Strength Last? - Yahoo Finance
Axsome (AXSM) Reports Positive Phase 3 Results for ADHD Treatmen - GuruFocus
Seeking Recession-Proof Stocks? RBC Suggests 2 Healthcare Stocks to Buy - Yahoo Finance
Norges Bank Purchases Shares of 403,026 Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Investor Alert: Class Action Lawsuits Against General Motors, DocGo, Estée Lauder, and Axsome Therapeutics Survive Motions to Dismiss — Johnson Fistel, PLLP Encourages Shareholders to Contact the Firm - GlobeNewswire
Wellington Management Group LLP Lowers Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
AAN 2025: Axsome Therapeutics’ treatment for Alzheimer’s agitation shows promise - Yahoo
Kuehn Law Encourages Investors of Axsome Therapeutics, Inc. to C - GuruFocus
ALERT: Grabar Law Office Investigates Claims on Behalf of Shareholders of Axsome Therapeutics - Bluefield Daily Telegraph
ALERT: Grabar Law Office Investigates Claims on Behalf of - GlobeNewswire
Axsome Therapeutics to Report First Quarter 2025 Financial Results on May 5 - The Manila Times
Axsome Earnings Alert: CNS Drug Leader Sets Q1 2025 Results Date - Stock Titan
Jefferies Initiates Coverage of Axsome Therapeutics (BMV:AXSM) with Buy Recommendation - Nasdaq
Axsome Therapeutics Inc Azioni (AXSM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Axsome Therapeutics Inc Azioni (AXSM) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Pizzie Nick | Chief Financial Officer |
Feb 14 '25 |
Option Exercise |
3.50 |
3,000 |
10,500 |
45,187 |
| Pizzie Nick | Chief Financial Officer |
Feb 13 '25 |
Sale |
129.86 |
12,000 |
1,558,320 |
42,187 |
| Pizzie Nick | Chief Financial Officer |
Feb 14 '25 |
Sale |
131.07 |
3,000 |
393,210 |
42,187 |
0.77%
0.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):